Enovis (NYSE:ENOV) Upgraded to “Buy” at Wall Street Zen

Enovis (NYSE:ENOV) was upgraded by equities researchers at Wall Street Zen from a “hold” rating to a “buy” rating in a research report issued on Saturday.

Several other research firms have also issued reports on ENOV. Needham & Company LLC lifted their target price on Enovis from $49.00 to $52.00 and gave the company a “buy” rating in a research note on Thursday, February 26th. Zacks Research lowered Enovis from a “strong-buy” rating to a “hold” rating in a report on Monday, June 1st. Evercore reissued an “outperform” rating and set a $36.00 target price on shares of Enovis in a report on Friday, May 8th. Wells Fargo & Company decreased their price target on Enovis from $42.00 to $40.00 and set an “overweight” rating for the company in a report on Friday, May 8th. Finally, BTIG Research reissued a “buy” rating and set a $39.00 target price on shares of Enovis in a research note on Friday, May 22nd. Seven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $44.50.

Enovis Stock Down 0.1%

Shares of NYSE:ENOV opened at $21.95 on Friday. The company has a 50-day moving average price of $23.89 and a 200 day moving average price of $24.30. The company has a current ratio of 2.04, a quick ratio of 1.05 and a debt-to-equity ratio of 0.87. Enovis has a 12 month low of $20.55 and a 12 month high of $36.82. The company has a market cap of $1.26 billion, a price-to-earnings ratio of -1.10 and a beta of 1.38.

Enovis (NYSE:ENOV) last released its earnings results on Thursday, May 7th. The company reported $0.89 EPS for the quarter, beating analysts’ consensus estimates of $0.82 by $0.07. The firm had revenue of $589.15 million for the quarter, compared to analysts’ expectations of $572.02 million. Enovis had a positive return on equity of 10.32% and a negative net margin of 49.92%.The company’s quarterly revenue was up 5.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.81 earnings per share. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. As a group, equities research analysts predict that Enovis will post 3.65 earnings per share for the current year.

Insider Buying and Selling at Enovis

In other Enovis news, insider Oliver Engert acquired 1,200 shares of the company’s stock in a transaction that occurred on Thursday, June 11th. The stock was purchased at an average price of $21.62 per share, for a total transaction of $25,944.00. Following the completion of the acquisition, the insider owned 51,840 shares of the company’s stock, valued at approximately $1,120,780.80. This trade represents a 2.37% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders have purchased a total of 4,200 shares of company stock valued at $92,084 in the last ninety days. Insiders own 2.90% of the company’s stock.

Institutional Investors Weigh In On Enovis

Hedge funds have recently bought and sold shares of the stock. AQR Capital Management LLC raised its holdings in Enovis by 12.5% in the first quarter. AQR Capital Management LLC now owns 63,671 shares of the company’s stock valued at $2,363,000 after acquiring an additional 7,072 shares in the last quarter. Goldman Sachs Group Inc. boosted its stake in Enovis by 37.6% in the first quarter. Goldman Sachs Group Inc. now owns 267,617 shares of the company’s stock valued at $10,226,000 after acquiring an additional 73,116 shares in the last quarter. Empowered Funds LLC grew its stake in Enovis by 13.0% during the 1st quarter. Empowered Funds LLC now owns 6,515 shares of the company’s stock worth $249,000 after buying an additional 749 shares during the last quarter. EverSource Wealth Advisors LLC grew its position in shares of Enovis by 125.4% during the second quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock worth $40,000 after acquiring an additional 707 shares during the last quarter. Finally, Amundi increased its stake in Enovis by 24,405.0% in the second quarter. Amundi now owns 9,802 shares of the company’s stock valued at $328,000 after purchasing an additional 9,762 shares during the period. Institutional investors and hedge funds own 98.45% of the company’s stock.

Enovis Company Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.